Searchable abstracts of presentations at key conferences in endocrinology

ea0052p32 | (1) | UKINETS2017

Impact of somatostatin analogues on quality of life in patients with neuroendocrine tumours

Shah Tahir , Osborne Hannah , Smith Stacey , Sagar Vandana

Somatostatin analogues (SSAs) are regularly used in the treatment of neuroendocrine tumours (NETs) to control the symptoms of hormonal hypersecretion. Evidence shows that SSAs can reduce tumour progression, and are therefore also being used in patients with non-functioning tumours. As many NETs present with advanced disease curative therapy is often not possible; therefore, assessing the impact of therapy on quality of life (QoL) is vital to patient management. This is particu...

ea0076p4 | Abstracts | CHD2021

The real value of the NET CNS led specialist carcinoid heart disease service: Making it happen

Smith Stacey , Vickrage Suzanne , Kemp-Blake Joanne , Coldham Chris

Introduction The diagnosis of carcinoid heart disease (CHD) is often made late and the patients are often deconditioned, with symptoms of fatigue, weight loss and refractory carcinoid symptoms. The challenge is then to improve the patient's condition by an enhanced pathway of prehabilitation and interventions, in order to consider surgical and medical therapies that can improve the patient's quality of life and prognosis. In 2018 due to the complexity of patients and increased...

ea0096p22 | Section | UKINETS2023

Successes and challenges in the combined neuroendocrine tumour and carcinoid heart disease service university hospitals birmingham: a neuroendocrine tumour clinical specialist nurse perspective

Vickrage Suzanne , Kemp-Blake Joanne , Coldham Chris , Smith Stacey

Introduction: The Birmingham Neuroendocrine Tumour (NET) and Carcinoid Heart Disease( CHD) services evolved into a combined and bespoke specialist service in 2018, with the introduction of the enhanced CHD pathway. This involved discussion at the CHD NET MDT , CHD work-up in the inpatient or outpatient setting and a clinical review in the bespoke CHD NET clinic. The CHD NET pathway is now embedded and well-established at our centre. We have a consistent flow o...

ea0038p168 | Neoplasia, cancer and late effects | SFEBES2015

Metastatic bowel carcinoid associated bilateral carcinoid heart disease

Jahagirdar Vidhya R , Kamal Ali D , Steeds Rick , Smith Stacey , Ayuk John

A 63-year-old Caucasian female was admitted with a 12-month history of exertional breathlessness, anxiety attacks, syncopal episodes, diarrhoea, fatigue, reduced appetite, two stones weight loss, and dry facial and truncal flushing. Investigations revealed raised Urine 5-HIAA of 116 (RR <50 μmol/24 h) and raised Chromogranin A of 48 (RR <6 nmol/l). CT scan revealed an extensive soft tissue mass encasing the upper abdominal aorta, compressing the inferior vena cava...

ea0068p7 | Abstracts | UKINETS2019

pNETs (Pancreatic Neuroendocrine tumours) in MEN1 (Multiple Endocrine Neoplasia): a single centre case series

Venkataraman Hema , Smith Stacey , Vickrage Suzanne , Kemp-Blake Joanne , Geh Ian , Shetty Shishir , Shah Tahir , Ayuk John

Introduction: MEN1 associated pNETs share a unique profile in comparison to sporadic pNETs. The literature on pNETs in MEN1 is evolving with on-going ambiguities in presentation and management. We present a case series of MEN1 associated pNETs from a tertiary centre of excellence for NETs in the UK.Methods: Institutional NET database was used for retrospective data analysis for all patients with pNETs associated with MEN1.Results: ...

ea0080p1 | Abstracts | UKINETS2021

Setting up of a national liver transplant programme for neuroendocrine tumour liver metastases in UK and Ireland: opportunities for clinical study and research

Shah Tahir , Moore Joanna , Venkataraman Hema , Caplin Martyn , Smith Stacey , O'Toole Dermot , Hoti Emir , Dasari Bobby , Ford Samuel , Mazzaferro Vincenzo , Gibbs Paul , Manas Derek , Isaac John , Thorburn Douglas

Background: Transplantation for cancer indications is evolving rapidly in UK and Ireland. Liver transplantation [LT] for unresectable neuroendocrine tumour liver metastases [NET LM] is one of three new cancer indications. It has the potential to significantly improve survival outcomes however, transplant benefit has likely been achieved only by highly experienced Centre(s). Since eligible patients for transplantation also have excellent prognosis with standard management, care...


Well-differentiated grade 3 neuroendocrine tumors (G3NET) – single centre experience from the UK

Venkataraman Hema , Lithgow Kirstie , Smith Stacey , Kemp-Blake Joanne , Vickrage Suzanne , Hughes Simon , Shetty Shishir , Elshafie Mona , Gadvi Rakesh , Kharkhanis Salil , Ayuk John , Geh Ian , Shah Tahir

Introduction: The WHO classification distinguishes G3NET as a separate entity. Literature on G3NETs is limited to case-reports and small case-series. We aimed to characterise G3NETs from a large tertiary centre.Methods: Retrospective analysis from NET database: 2012–2019. All referrals are discussed at a specialist NET-MDT before entry into clinical pathway. Core NET-MDT consists of a radiologist, nuclear-medicine radiologist, histopathologist, spec...

ea0076p5 | Abstracts | CHD2021

Nutritional recovery is essential for successful management of patients with advanced carcinoid heart disease

Shah Husnain , Mair Reena , Arif Sayqa , Smith Stacey , Vickrage Suzanne , Kemp-Blake Joanne , Denham Samuel , Oelofse Tessa , Singh Harjot , Singh Stephen , Steeds Richard , Shah Tahir

Introduction Chronic heart failure is a catabolic state leading to cachexia in 5-15% of patients, predicting poor survival outcomes. Malnutrition affects 40% of patients with NETs and 58% with carcinoid syndrome (CS). Case 45M with severe carcinoid heart disease, on referral and admission was cachectic with BMI of 16, having lost 32 kg or 30% of body weight, meeting 50% of dietary requirements and at risk of refeeding syndrome. Nasogastric feeding (NG) w...

ea0087p9 | Poster Presentations | UKINETS2022

Ocular neuroendocrine tumour metastases – presentation & outcome

Shah Husnain , Roji Mohamad , Ekmekcioglu Ozgul , Ayuk John , Smith Stacey , Khan Zaira , Vickrage Suzanne , Kemp-Blake Joanne , Humphries Sian , Hughes Simon , Diaz-Cano Salvador , Elshafie Mona , Karkhanis Salil , Shetty Shishir , Geh Ian , Shah Tahir

Introduction: Here we present our experience of managing patients with orbital well-differentiated neuroendocrine tumour (NET) metastases.Methods: Six patients were identified from the hospital NET database: four male; two female.Results: Median age at diagnosis of primary NET: 69.5 years (range: 40-74 years). Three patients were alive at time of data capture. Of those who passed away: mean survival from diagnosis of primary NET = ...

ea0072p4 | (1) | UKINETS2020

Telotristat in the management of Carcinoid diarrhoea – real world experience of patients from an ENETs centre of excellence in Neuroendocrine tumours.

Khanna Amardeep , Cianci Nicole , Abbas Shah Husnain , Goel Ashish , Jebril Asma , Chauhan Jessica , Pipe Michelle , Shetty Shishir , Weston Christopher , Venkataraman Hema , Smith Stacey , Vickrage Suzanne , Kemp-Blake Joanne , Shah Tahir

Carcinoid syndrome occurs in 20% patients, presenting with flushing, abdominal pain, diarrhoea, and wheeze and can be challenging to manage. The standard of care for carcinoid syndrome is somatostatin analogues (SSAs) with add-on Creon, codeine and loperamide therapy. Nonetheless, half of patients experience debilitating diarrhoea. Telotristat-ethyl is a peripheral tryptophan-hydroxylase inhibitor approved for treatment of diarrhoea, supported by Phase 3 clinical trials but la...